Exelixis, Inc. Aktie News

Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis' R&D activities and outline the company's strategy to advance future ...

Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.

Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with E...

Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but introduce the first immunotherapy approach in refractory mCRC, despite notable toxicity concerns. EXEL's pipeline strength is buoyed by zanzalintinib, but real-world adoption and broader success rem...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference: Exelixis is sched...

Exelixis, Inc. ( EXEL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Michael Morrissey - CEO, President & Director Christopher Senner - Executive VP & CFO Dana Aftab - Executive Vice President of Research & Development P. Haley - Executive Vice President of Commercial Conference Call Parti...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategi...